Ionis Pharmaceuticals IONS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's total equity?
- Ionis Pharmaceuticals (IONS) reported total equity of $491.41M in Q1 2026.
- How has Ionis Pharmaceuticals's total equity changed year-over-year?
- Ionis Pharmaceuticals's total equity increased by 3.3% year-over-year, from $475.73M to $491.41M.
- What is the long-term trend for Ionis Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total equity has grown at a -8.0% compound annual growth rate (CAGR), from $743.28M to $489.09M.
- What does total equity mean?
- The net value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- An increasing trend generally signals value creation, whereas a declining trend may indicate persistent losses or excessive share repurchases.
- How does total equity compare across companies?
- Standard metric for assessing the financial foundation of any public corporation.